The end of trajectory of pharma. A case study of Aventis
dc.rights.license | open | |
dc.contributor.author | LEAVER, Adam | |
hal.structure.identifier | Groupe de Recherche en Economie Théorique et Appliquée [GREThA] | |
dc.contributor.author | MONTALBAN, Matthieu
IDREF: 076469336 | |
dc.date.accessioned | 2020-02-17T11:44:45Z | |
dc.date.available | 2020-02-17T11:44:45Z | |
dc.date.conference | 2006-10-19 | |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/2726 | |
dc.language.iso | en | |
dc.title.en | The end of trajectory of pharma. A case study of Aventis | |
dc.type | Communication dans un congrès avec actes | |
dc.subject.hal | Sciences de l'Homme et Société/Economies et finances | |
bordeaux.institution | Université de Bordeaux | |
bordeaux.country | FR | |
bordeaux.title.proceeding | GSK, Merck and Sanofi, ESEMK | |
bordeaux.peerReviewed | oui | |
hal.identifier | hal-00257814 | |
hal.version | 1 | |
hal.origin.link | https://hal.archives-ouvertes.fr//hal-00257814v1 | |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.au=LEAVER,%20Adam&MONTALBAN,%20Matthieu&rft.genre=proceeding |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |